{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:44:55Z","timestamp":1792014295290,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,6,17]],"date-time":"2009-06-17T00:00:00Z","timestamp":1245196800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1007\/s00198-009-0984-0","type":"journal-article","created":{"date-parts":[[2009,6,16]],"date-time":"2009-06-16T17:00:19Z","timestamp":1245171619000},"page":"647-653","source":"Crossref","is-referenced-by-count":40,"title":["Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX\u2122"],"prefix":"10.1007","volume":"21","author":[{"given":"R. A.","family":"Adler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. W.","family":"Hastings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. I.","family":"Petkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,6,17]]},"reference":[{"issue":"Suppl 3","key":"984_CR1","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S1098-3597(06)80018-9","volume":"8","author":"RA Adler","year":"2006","unstructured":"Adler RA (2006) The need for increasing awareness of osteoporosis in men. Clin Cornerstone 8(Suppl 3):S7\u2013S13","journal-title":"Clin Cornerstone"},{"key":"984_CR2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0022-5347(01)65165-6","volume":"157","author":"HW Daniell","year":"1997","unstructured":"Daniell HW (1997) Osteoporosis after orchiectomy for prostate cancer. J Urol 157:439\u2013444","journal-title":"J Urol"},{"key":"984_CR3","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1210\/jcem.87.8.8782","volume":"87","author":"D Mittan","year":"2002","unstructured":"Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM (2002) Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 87:3656\u20133661","journal-title":"J Clin Endocrinol Metab"},{"key":"984_CR4","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1210\/jc.2005-0183","volume":"90","author":"SL Greenspan","year":"2005","unstructured":"Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM (2005) Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90:6410\u20136417","journal-title":"J Clin Endocrinol Metab"},{"key":"984_CR5","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0022-5347(05)00033-9","volume":"175","author":"MR Smith","year":"2006","unstructured":"Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J (2006) Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 175:136\u2013139","journal-title":"J Urol"},{"key":"984_CR6","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00198-004-1799-7","volume":"16","author":"AM Lopez","year":"2005","unstructured":"Lopez AM, Pena MA, Hernandez R, Val F, Martin B, Riancho JA (2005) Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int 16:707\u2013711","journal-title":"Osteoporos Int"},{"key":"984_CR7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"352","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154\u2013164","journal-title":"N Engl J Med"},{"key":"984_CR8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jama.300.2.173","volume":"300","author":"GL Lu-Yao","year":"2008","unstructured":"Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL (2008) Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 300:173\u2013181","journal-title":"JAMA"},{"key":"984_CR9","doi-asserted-by":"crossref","first-page":"680","DOI":"10.7326\/0003-4819-148-9-200805060-00008","volume":"148","author":"A Qaseem","year":"2008","unstructured":"Qaseem A, Snow V, Shekelle P, Hopkins RH Jr, Forciea MA, Owens DK (2008) Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med 148:680\u2013684","journal-title":"Ann Intern Med"},{"key":"984_CR10","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/ncprheum0923","volume":"4","author":"MC Hochberg","year":"2008","unstructured":"Hochberg MC, Adler RA (2008) Screening for osteoporosis in men: comment on the American College of Physician\u2019s clinical guidelines. Nat Clin Pract Rheumatol 4:626\u2013627","journal-title":"Nat Clin Pract Rheumatol"},{"key":"984_CR11","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1210\/jc.2006-0173","volume":"91","author":"HA Fink","year":"2006","unstructured":"Fink HA, Ewing SK, Ensrud KE, Barrett-Connor E, Taylor BC, Cauley JA, Orwoll ES (2006) Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab 91:3908\u20133915","journal-title":"J Clin Endocrinol Metab"},{"key":"984_CR12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00198-008-0564-8","volume":"19","author":"E Siris","year":"2008","unstructured":"Siris E, Delmas PD (2008) Assessment of 10-year absolute fracture risk: a new paradigm with worldwide application. Osteoporos Int 19:383\u2013384","journal-title":"Osteoporos Int"},{"key":"984_CR13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00198-008-0559-5","volume":"19","author":"B Dawson-Hughes","year":"2008","unstructured":"Dawson-Hughes B, Tosteson ANA, Melton LJ III, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 19:449\u2013458","journal-title":"Osteoporos Int"},{"key":"984_CR14","first-page":"133901338","volume":"16","author":"C Laet De","year":"2005","unstructured":"De Laet C, Kanis JA, Oden A et al (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16:133901338","journal-title":"Osteoporos Int"},{"key":"984_CR15","unstructured":"ISCD (2007) ISCD official positions 2007. www.iscd.org . Accessed August 2008"},{"key":"984_CR16","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00198-007-0550-6","volume":"19","author":"ANA Tosteson","year":"2008","unstructured":"Tosteson ANA, Melton LJ III, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Cost-effective osteoporosis treatment thresholds: the U.S. perspective from the National Osteoporosis Foundation Guide Committee. Osteoporos Int 19:437\u2013447","journal-title":"Osteoporos Int"},{"key":"984_CR17","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","volume":"343","author":"E Orwoll","year":"2000","unstructured":"Orwoll E, Ettinger M, Weiss S et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604\u2013610","journal-title":"N Engl J Med"},{"key":"984_CR18","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s00296-005-0004-4","volume":"26","author":"JD Ringe","year":"2006","unstructured":"Ringe JD, Faber H, Farahmand P, Dorst A (2006) Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 26:296\u2013300","journal-title":"Rheumatol Int"},{"key":"984_CR19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","volume":"18","author":"ES Orwoll","year":"2003","unstructured":"Orwoll ES, Scheele WH, Paul S et al (2003) The effect of teriparatide [human parathyroid hormone (1\u201334)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9\u201317","journal-title":"J Bone Miner Res"},{"key":"984_CR20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00198-005-1919-z","volume":"17","author":"JK Tracy","year":"2006","unstructured":"Tracy JK, Meyer WA, Grigoryan M et al (2006) Racial differences in the prevalence of vertebral fractures in older men: the Baltimore Men\u2019s Osteoporosis Study. Osteoporos Int 17:99\u2013104","journal-title":"Osteoporos Int"},{"key":"984_CR21","unstructured":"Sridhar G, Adera T, Ramakrishnan R, Roberts JD, Nelson CMK, Masho SW (2008) Racial disparities in prostate cancer survival: a meta-analysis. American Public Health Association Annual Meeting #190878 (abstract)"},{"key":"984_CR22","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1210\/jc.2007-1402","volume":"93","author":"SL Greenspan","year":"2008","unstructured":"Greenspan SL (2008) Approach to the prostate cancer patient with bone disease. J Clin Endocrinol Metab 93:2\u20137","journal-title":"J Clin Endocrinol Metab"},{"key":"984_CR23","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","volume":"169","author":"MR Smith","year":"2003","unstructured":"Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner S (2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169:2008\u20132012","journal-title":"J Urol"},{"key":"984_CR24","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1210\/jc.2003-032058","volume":"89","author":"MR Smith","year":"2004","unstructured":"Smith MR, Fallon MA, Lee H, Finkelstein JS (2004) Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 89:3841\u20133846","journal-title":"J Clin Endocrinol Metab"},{"key":"984_CR25","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","volume":"146","author":"SL Greenspan","year":"2007","unstructured":"Greenspan SL, Nelson JB, Trump DL, Resnick NM (2007) Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer. Ann Intern Med 146:416\u2013424","journal-title":"Ann Intern Med"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-009-0984-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-009-0984-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-009-0984-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T19:01:05Z","timestamp":1558638065000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-009-0984-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,17]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["984"],"URL":"https:\/\/doi.org\/10.1007\/s00198-009-0984-0","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,17]]}}}